Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Summary

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

Timeline

Start

2023-10-31

Primary completion

2029-12

Completion

2029-12

Publications

• Lee YJ, Lee YY, Park JY, Cho HW, Lim MC, Kim MK, Lee JM, Lee JY. A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC). J Gynecol Oncol. 2025 May;36(3):e35. doi: 10.3802/jgo.2025.36.e35. Epub 2024 Oct 23.

Drugs

Indications